Klaus R. Dr Veitinger 391 Shares of Intercept Pharmaceuticals Stock (ICPT)
Intercept Pharmaceuticals (NASDAQ:ICPT) Director Klaus R. Dr Veitinger 391 shares of Intercept Pharmaceuticals stock in a transaction dated Thursday, July 10th. Following the completion of the , the director now directly owns 1,780 shares in the company, valued at approximately $390,087. The was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.
A number of research firms have recently commented on ICPT. Analysts at Goldman Sachs initiated coverage on shares of Intercept Pharmaceuticals in a research note on Wednesday, July 2nd. They set a “neutral” rating and a $265.00 price target on the stock. Separately, analysts at RBC Capital initiated coverage on shares of Intercept Pharmaceuticals in a research note on Monday, June 30th. They set an “outperform” rating and a $425.00 price target on the stock. Finally, analysts at Summer Street reiterated a “buy” rating on shares of Intercept Pharmaceuticals in a research note on Friday, June 27th. Three analysts have rated the stock with a hold rating and seven have given a buy rating to the company’s stock. The company has an average rating of “Buy” and an average price target of $457.56.
Intercept Pharmaceuticals (NASDAQ:ICPT) traded down 0.54% during mid-day trading on Friday, hitting $222.20. The stock had a trading volume of 214,300 shares. Intercept Pharmaceuticals has a 52 week low of $42.41 and a 52 week high of $497.00. The stock’s 50-day moving average is $254.1 and its 200-day moving average is $287.5. The company’s market cap is $4.686 billion.
Intercept Pharmaceuticals (NASDAQ:ICPT) last issued its quarterly earnings data on Wednesday, May 7th. The company reported ($1.59) EPS for the quarter, missing the Thomson Reuters consensus estimate of ($0.72) by $0.87. On average, analysts predict that Intercept Pharmaceuticals will post $-14.82 earnings per share for the current fiscal year.
Intercept Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of therapeutics to treat chronic liver diseases utilizing its bile acid chemistry.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.